Acting Governor of Hodeida Mohammed Ayash Quhaim with members of the UN mission. Photo: AFP/Getty Images

A dispute over Houthi withdrawals from critical ports in Yemen is threatening the success of a deal negotiated late last year with the country's internationally recognized government.

Why it matters: The Stockholm agreement, considered a breakthrough when announced in December, was intended to improve Yemen’s dire humanitarian situation and build confidence between the government and the Iran-backed Houthis. But scant progress has been made, raising concerns about the UN’s ability to broker a permanent peace between the warring parties.

Background: For the past 5 months, Yemen's government has pointed to the Houthis’ reluctance to withdraw from the Yemeni ports of Hodeidah, Salif and Rass-Issaas as evidence of their insincerity.

Where it stands: The Houthi withdrawal finally began last weekend, and UN Special Envoy Martin Griffiths briefed the Security Council on Wednesday on its progress.

  • Yemen’s government declared the withdrawal a sham, on the basis that it was prevented from monitoring and verifying the operation in “violation” of their agreement, leaving Houthi loyalists in charge.
  • The UN views any Houthi pullback as vital to ensuring the flow of humanitarian aid. It would also allow for removing mines from around the ports and responding to a derelict oil tanker anchored off Salif that could explode at any time.

What’s next: Yemen's government has been left in a difficult position after the withdrawal, worried about the UN's ability to act as a neutral arbiter and the threat posed by Houthi forces positioned just outside Hodeidah.

  • Objections aside, the government is likely to withdraw as planned a few kilometers back from where they are currently stationed in Hodeidah’s outskirts, while pressing for neutral port management by professional staff and law enforcement officials employed before the Houthi takeover in 2014.
  • The UN's ceasefire statement has already been contradicted by reports of clashes between the Yemeni government and Houthi forces in Hodeidah. Absent an enforcement mechanism for the UN to hold violators accountable, the violence could quickly escalate.

The bottom line: Unless the special envoy can guarantee the neutrality and safety of the port, the most critical part of the Stockholm agreement is in danger of collapse.

Fatima Abo Alasrar is a senior analyst at the Arabia Foundation.

Go deeper

Updated 51 mins ago - Politics & Policy

Coronavirus dashboard

Illustration: Aïda Amer/Axios

  1. Politics: Chris Christie: Wear a mask "or you may regret it — as I did" — Senate Democrats block vote on McConnell's targeted relief bill.
  2. Business: New state unemployment filings fall.
  3. Economy: Why the stimulus delay isn't a crisis (yet).
  4. Health: FDA approves Gilead's remdesivir as a coronavirus treatment How the pandemic might endMany U.S. deaths were avoidable.
  5. Education: Boston and Chicago send students back home for online learning.
  6. World: Spain and France exceed 1 million cases.

FBI: Russian hacking group stole data after targeting local governments

FBI Headquarters. Photo: Mark Wilson/Getty Images

Energetic Bear, a Russian state-sponsored hacking group, has stolen data from two servers after targeting state and federal government networks in the U.S. since at least September, the FBI and Cybersecurity and Infrastructure Security Agency said on Thursday.

Driving the news: Director of National Intelligence John Ratcliffe announced Wednesday that Iran and Russia had obtained voter registration information that could be used to undermine confidence in the U.S. election system.

FDA approves Gilead's remdesivir as a coronavirus treatment

A production line of Remdesivir. Photo: Fadel Dawood/picture alliance via Getty Images

Gilead Sciences on Thursday received approval from the Food and Drug Administration for remdesivir, an antiviral treatment that has shown modest results against treating COVID-19.

Why it matters: It's the first and only fully FDA-approved drug in the U.S. for treating the coronavirus.

Get Axios AM in your inbox

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Subscription failed
Thank you for subscribing!